Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
GLP-1 receptor agonist (GLP-1RA) have been developed to address the global burden of obesity and are renowned for their safety and efficacy. These medications influence hunger and satiety, reducing energy intake and promoting weight loss. Despite their benefits, GLP-1RAmay cause a slowed gastric emptying, leading to gastrointestinal symptoms. This study examines how food properties and meal composition affect these symptoms. Dietary recommendations are provided, particularly for evening meals, focusing on how different foods and nutrients can influence the rate of gastric emptying, to improve patient compliance and prevent interruption in weight loss.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Foods with lower viscosity (i.e., that flow easily), fewer calories, lower glycemic index, and higher water content (e.g., certain fruits and vegetables and fruits) can facilitate faster gastric emptying [141].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients accustomed to consuming large volumes of low-energy-density foods are likely to exacerbate GLP-1-induced gastric stasis and postprandial discomfort, supporting a shift toward nutrient-dense, lower-volume feeding patterns during the titration phase [27,33,37].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Foods high in protein or fat can further slow gastric emptying, which can promote weight reduction and metabolism but also worsen constipation, potentially requiring temporary limitation of these foods [141].”
From Nutritional priorities to support GLP ‐1 therapy for obesity: A joint Advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society (2025) · cites this paper as [141]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“GI side effects—including nausea, vomiting, bloating, and diarrhea—are profoundly dose-dependent and frequently exacerbated by specific macronutrient profiles [27,33].”
From Adherence and Persistence with GLP-1-Based Therapies: International Real-World Evidence and the Role of Nutritional and Lifestyle Support—A Narrative Review (2026) · cites this paper as [33]
Experimental — accuracy not yet measured
11 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European Guidelines for Obesity Management in Adults
Yumuk, V., Tsigos, C., Fried, M., Schindler, K., Busetto, L., Micic, D., & Toplak, H. (2015) · Obesity Facts · doi:10.1159/000442721 · Cited by 3,432
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1411892 · Cited by 2,724
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“9 It is released in response to meal intake leading to increased satiety and better glucose metabolism regulation.”
The Discovery and Development of Liraglutide and Semaglutide
Knudsen, L. B., & Lau, J. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00155 · Cited by 970 · cited 1×
“13,15 Liraglutide , the first GLP-1RAs approved for weight management, acts as a long-acting agonist on its receptor, reducing appetite, delaying gastric emptying, and increasing pancreatic insulin secretion.”
Glucagon-like peptide 1 in health and disease
Andersen, A., Lund, A., Knop, F. K., & Vilsbøll, T. (2018) · Nature Reviews Endocrinology · doi:10.1038/s41574-018-0016-2 · Cited by 543
Sodhi, M., Rezaeianzadeh, R., Kezouh, A., & Etminan, M. (2023) · JAMA · doi:10.1001/jama.2023.19574 · Cited by 471 · cited 1×
“8,37,38 If gastrointestinal adverse events occur, clinicians should prolong the titration period or avoid dose increases until the effects subside.”
Friedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427 · cited 1×
“17 An increased incidence of gallstones has been reported in patients treated with Liraglutide, along with a potential association between mild pancreatitis and rapid weight loss.”
Bettge, K., Kahle, M., Abd El Aziz, M. S., Meier, J. J., & Nauck, M. A. (2017) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12824 · Cited by 374 · cited 2×
“11,18 Therefore, understanding the mechanisms underpinning these issues is crucial.”
Advances in the physiology of gastric emptying
Goyal, R. K., Guo, Y., & Mashimo, H. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13546 · Cited by 369
Gorgojo-Martínez, J. J., Mezquita-Raya, P., Carretero-Gómez, J., Castro, A., Cebrián-Cuenca, A., de Torres-Sánchez, A., García-de-Lucas, M. D., Núñez, J., Obaya, J. C., Soler, M. J., et al. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm12010145 · Cited by 358 · cited 3×
“8 In this regard, a group of medical experts, including endocrinologists, nephrologists, general practitioners, cardiologists, internal medicine specialists, and nurses, recently have developed dietary and behavioral guidelines to prevent or minimize gastrointestinal effects and avoid medication…”
Research works printed but not linked: 3
- Travagli, 2006, Annu Rev Physiol, 68, 279, 10.1146/annurev.physiol.68.040504 · doi:10.1146/annurev.physiol.68.040504
- Kamiya, 2007, Nihon Rinsho, 65, 836
- 2011, Healthy Eating Plate, Chan School of Public Health
Cited by
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · The American Journal of Clinical Nutrition · doi:10.1016/j.ajcnut.2025.04.023 · Cited by 154
“Foods high in protein, fat, or fiber can further slow gastric emptying, which can be helpful for weight reduction and metabolism but can also worsen constipation, potentially requiring temporary limitation of these foods [132].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity · doi:10.1002/oby.24336 · Cited by 143
“Dietary recommendations should be adjusted based on the rate of weight reduction, nutrient status, individual tolerance, and treatment response.”
Rosen, C. J., & Ingelfinger, J. R. (2026) · New England Journal of Medicine · doi:10.1056/nejmra2500106 · Cited by 135
Lifestyle Medicine for Obesity in the Era of Highly Effective Anti-Obesity Treatment
Sannidhi, D., Abeles, R., Andrew, W., Bonnet, J. P., Vitale, K., Niranjan, V., Gulati, M., Pauly, K., Moran, R., Alexander, L., et al. (2025) · Nutrients · doi:10.3390/nu17142382 · Cited by 29
“While fiber is a nutrient of concern and intake should be encouraged, higher fiber intake can sometimes exacerbate side effects [101].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J., Butsch, W. S., Christensen, S., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100181 · Cited by 28
Sievenpiper, J. L., Ard, J. D., Blüher, M., Chen, W., Dixon, J. B., Fitch, A., Gigliotti, L., Khunti, K., Lecube, A., Lean, M., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100228 · Cited by 56
“…not hungry, avoiding high-fat or spicy foods (particularly during the dose titration period), minimizing intake of alcohol and fizzy drinks (especially in case of nausea or dyspepsia), and maintaining adequate hydration and fibre intake may help relieve mild-to-moderate GI symptoms [49,140,143].”
Mozaffarian, D., Agarwal, M., Aggarwal, M., Alexander, L., Apovian, C. M., Bindlish, S., Bonnet, J. P., Butsch, W. S., Christensen, S. M., Gianos, E., et al. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2026.100269 · Cited by 41
Spreckley, M., Ruggiero, C. F., & Brown, A. (2026) · Obesity Reviews · doi:10.1111/obr.70079 · Cited by 16
“Gastrointestinal side effects, such as nausea, early satiety, and altered taste, are common and may compromise dietary intake, increasing the risk of deficiencies [12].”
InfluentialJohnson, B. V. B., Milstead, M., Kreider, R., & Jones, R. (2025) · Obesity Pillars · doi:10.1016/j.obpill.2025.100209 · Cited by 27
“Current clinical guidance focuses primarily on managing gastrointestinal side effects during GLP-1RA treatment, with some nutrition considerations recommended based on previous literature in weight loss science [7 – 11].”
Barrea, L., Annunziata, G., Verde, L., Galasso, M., Savastano, S., Colao, A. A. L., & Muscogiuri, G. (2025) · Current Obesity Reports · doi:10.1007/s13679-025-00667-3 · Cited by 26
Minnetti, M., Barazzoni, R., Batsis, J. A., Busetto, L., Yumuk, V., Poggiogalle, E., Weijs, P. J. M., & Donini, L. M. (2025) · Obesity Facts · doi:10.1159/000548370 · Cited by 15
“Ensuring patients understand how to adjust their eating habits and manage sensations of satiety after starting IMs is crucial for optimizing adherence and reducing drop-out [67].”
Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review
Dias, D. D., Vasconcelos, A. R., Souza, A. C. R., Menezes, C. D., Silva, I. S. T. E., & Name, J. J. (2025) · Obesities · doi:10.3390/obesities5040088 · Cited by 8
“Furthermore, long-term therapy is associated with nutritional deficiencies, lean mass loss, and frequent GI adverse events, including nausea, vomiting, diarrhea, and constipation, which may affect up to 70–85% of patients and lead to treatment discontinuation [22,38,41,60,61].”
InfluentialZambrano-Villacres, R., Campuzano-Donoso, M., Reytor-González, C., Rossetti, G., Cobellis, L., Cobellis, F., Pilone, V., Simancas‐Racines, D., & Schiavo, L. (2026) · Nutrients · doi:10.3390/nu18111751 · Cited by 8
“Smaller, more frequent meals; slower eating pace; careful titration of dietary fat; and attention to food texture can significantly improve tolerability [55,56].”
InfluentialMind the Plateau: A Mathematical Modeling Analysis of Long-Term GLP-1 Receptor Agonist Treatment
Hubert, P. A., Coleman, C. D., Grosicki, G. J., Kiel, J., Shepherd, M., Lofton, H. F., Heymsfield, S. B., Thomas, J. G., Dhurandhar, N. V., & Jonnalagadda, S. S. (2026) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2026.156366 · Cited by 5
Kennedy, C., Moyer, K., & Herdes, R. E. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11356 · Cited by 8
“19,34 Reducing nutrient ‐ poor carbohydrate sources (such as processed foods high in refined grains and added sugars) and eliminating sugar ‐ sweetened beverages are encouraged to regulate blood glucose and aid in weight management.”
InfluentialWang, Y., Liu, J., Verbeke, K., Gasaly, N., Akkerman, R., & de Vos, P. (2026) · Advances in Nutrition · doi:10.1016/j.advnut.2026.100647 · Cited by 11
“…are encouraged to choose low-fiber vegetables, avoid whole grains and high-fiber legumes during dose escalation, maintain adequate hydration, pair meals with moderate portions of complex carbohydrates and low-fat proteins, and increase the drug dose gradually to minimize GI discomfort [127].”
Simancas‐Racines, D., Campuzano-Donoso, M., Rossetti, G., Cobellis, L., Pilone, V., Fascì-Spurio, F., Gavilanes, D. J., Soria, C., Reytor-González, C., & Schiavo, L. (2026) · Obesity Pillars · doi:10.1016/j.obpill.2026.100290 · Cited by 3
“Gastrointestinal symptoms represent another important pathway through which incretin-based therapies may influence dietary intake [85,86].”
Mogna-Peláez, P., & Guasch‐Ferré, M. (2026) · Journal of Nutrition · doi:10.1016/j.tjnut.2026.101684 · Cited by 4
“Low fiber and fluid intake may further exacerbate GI problems such as constipation, bloating, and nausea, creating a cycle in which patients eat even less [7,14,20].”
Dziewierz, A., & Siudak, Z. (2026) · Nutrients · doi:10.3390/nu18111761 · Cited by 3
“When a patient receiving a high-dose GLP-1 RA consumes a high-fat meal, the combined effect of pharmacological and endogenous lipid-mediated signaling can produce profound gastric stasis [27,33].”
InfluentialImpact of GLP-1 receptor agonists on gastrointestinal function and symptoms
Frazier, R., & Hasler, W. L. (2025) · Expert Review of Gastroenterology & Hepatology · doi:10.1080/17474124.2025.2579117 · Cited by 4
“The entries in this table represent the combined recommendations from several references cited in this article including [81], [87], [88], [89], and [111]. retained gastric contents (OR 6.30, 95% CI 5.30–7.49), and greater needs to abort (OR 5.50, 95% CI 3.25–9.32) or repeat (OR 2.19, 95% CI…”
InfluentialMercado, D. O., Fadda, M., Beltrame, B., Tosi, M., Bruno, A., Scala, C. D., Travaglia, G., Vitale, A., di Cola, R. S., Boschetti, S., et al. (2026) · Dietetics · doi:10.3390/dietetics5010017 · Cited by 2
Glucagon-Like Peptide-1 Receptor Agonists: Their Potential Role in Prediabetes
Panou, T., Gouveri, E., Popovic, D. S., Papazoglou, D., & Παπάνας, Ν. (2026) · Diabetes Therapy · doi:10.1007/s13300-026-01865-5 · Cited by 2
“Furthermore, minor dietary adaptations and adequate hydration could at least partly relieve adverse events [38, 39].”
Olowo‐Oribi, B. A., & Salway, R. J. (2025) · Academic Emergency Medicine · doi:10.1111/acem.70088 · Cited by 3
“If side effects remain unmanageable, switching to an alternative GLP-1 receptor agonist or discontinuing the medication may be appropriate, depending on the patient's response [15, 16].”
GLP-1 Receptor Agonists: Therapeutic Potential and Emerging Concerns
Nowak, K., Łupina, K., Kalisz, A., Ilkiewicz, Ł., & Janczura, J. (2026) · Current Pharmacology Reports · doi:10.1007/s40495-026-00459-w · Cited by 2
Sancho-Haro, E. S., Muñoz-López, M., Baz-Valle, E., Villanueva-Tobaldo, C. V., Tornero-Aguilera, J. F., López-Gil, J. F., López‐Moreno, M., Martín-Rodríguez, A., & Clemente‐Suárez, V. J. (2026) · Pharmaceuticals · doi:10.3390/ph19060897 · Cited by 2
Minnetti, M., Piciocchi, C., Frigerio, F., Vincenzo, O. D., Muzzioli, L., Poggiogalle, E., Migliaccio, S., & Donini, L. M. (2025) · L Endocrinologo · doi:10.1007/s40619-025-01653-6
Mercadal-Orfila, G., Taltavull, J. L., Cuatrecasas, G., García, J. M., Maestre-Fullana, M. A., & Herrera-Pérez, S. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1731194 · Cited by 5
GLP-1 receptor agonists: The good, the bad, and the ugly—A comprehensive guide for NPs
Rodriguez, M. E., Lavell, J., & Foreman, R. M. (2026) · The Nurse Practitioner · doi:10.1097/01.npr.0000000000000430
Čermáková, E. (2026) · Medicína pro praxi · doi:10.36290/med.2026.025
Balasubaramaniam, V., Scobie, M., O’Kane, M. P. M., Graham, Y., Robertson, A. G., & Mahawar, K. K. (2026) · Nutrients · doi:10.3390/nu18162643
“Systematic reviews and clinical guidance identify nausea, vomiting, diarrhoea, and constipation as frequent adverse effects of GLP-1 RAs and dual incretin therapies [32,34,44–47].”
Qureshi, S., Sajid, M., Khan, H. R., Greene, S. J., Fudim, M., McCann, G. P., Squire, I. B., Waqas, S. A., Khan, M. S., Lawson, C., et al. (2026) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2026.10.001
Decoding the Safety Profile of GLP-1 Receptor Agonists: Facts, Myths, and Ongoing Controversies
Kounatidis, D. C., Vallianou, N. G., Kouveletsou, M., Kontrafouri, P., Stamatopoulos, V., Rebelos, E., Diakoumopoulou, E., & Dalamaga, Μ. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00770-z
Metadata
- Authors
- Gentinetta, S., Sottotetti, F., Manuelli, M., & Cena, H.
- Affiliations
- Novo Nordisk (Italy) (IT)
- University of Pavia (IT)
- Istituti Clinici Scientifici Maugeri (IT)
- Corresponding author
- Sottotetti, Francesca
- Venue
- Diabetes, Metabolic Syndrome and Obesity
- Publisher
- Informa UK Limited
- Published
- 2024-12
- Volume
- Volume 17
- Pages
- 4817-4824
- ISSN
- 1178-7007 (ISSN-L)
- PMC
- PMC11668918
- OpenAlex
- W4405544542
- Cited by
- 32
- References
- 38
- Citations by year
- 2026: 18 · 2025: 14
- FWCI
- 9.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
- Funders
- Novo Nordisk
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- GLP-1 receptor agonists, gastrointestinal symptoms, delayed gastric emptying, dietary recommendations, meal composition, food properties, dinner, weight loss, obesity, satiety, medication adherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
